This is in the context whereby the tumor cells themselves do not respond to TLR9 signaling; therefore, combining such treatment with tumor profiling to identify TLR9 nonresponsive tumors would be beneficial to avoid any potential enhancement of a tumor’s invasive properties. The gene discussed is TLR9; the disease is neoplasm.